Back to Newsroom

Cempra to Present Late-Breaker on Solithromycin Reducing Inflammation in an Animal Model for Cancer Chemotherapy-Induced Lung Injury

Study Suggests Clinical Uses of Solithromycin Beyond Bacterial Infections
Presentation at the American Thoracic Society 2014 International Conference

CHAPEL HILL, N.C., March 27, 2014 (GLOBE NEWSWIRE) — Cempra, Inc., (Nasdaq:CEMP) today announced a late-breaker presentation demonstrating that solithromycin reduced inflammation in an animal model for inflammatory lung disease at the American Thoracic Society (ATS) 2014 International Conference in San Diego.